Prostate Cancer Lymphangitic Pulmonary Carcinomatosis

Abstract A 51-year-old man diagnosed with high-grade, high-volume metastatic castration-sensitive prostate adenocarcinoma received pelvic radiation, androgen deprivation therapy, and intravenous docetaxel. Serum prostate-specific antigen became undetectable following treatment. Within a year, his cancer progressed to castration-resistant disease, and he was treated with oral abiraterone acetate 1000 mg and prednisone 10 mg daily. Despite this, the serum prostate-specific antigen rose from 0.03 to 1.39 μg/L, and 18F-DCFPyL and 18F-FDG PET/CT showed progression. While 18F-DCFPyL uptake may be seen in aggressive disease, 18F-FDG portends poor prognosis. Despite intravenous platinum-based chemotherapy, the patient died of respiratory failure 20 months after his initial diagnosis.

Prostate Cancer Lymphangitic Pulmonary Carcinomatosis Journal Articles